H.C. Wainwright raised the firm’s price target on Roivant Sciences to $18 from $17 and keeps a Buy rating on the shares. The analyst says drepocitinib demonstrated “best-in-class” potential in noninfectious uveitis. “With this important win, we now look ahead to brepocitinib’s Phase 3 readout in dermatomyositis with data expected in 2025,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
- Roivant Sciences to replace Sunrun in the S&P 400 at open on 4/1
- Sunrun to replace PGT Innovations in the S&P 600 at open on 4/1
- Roivant Sciences call volume above normal and directionally bullish
- JPMorgan reiterates Overweight ratings on Roivant, Immunovant
